36057-45-1

Basic information

• Product Name: 3,5-DiMethoxypicolinonitrile
• Synonyms: 3,5-DiMethoxypicolinonitrile
• CAS NO: 36057-45-1
• Molecular Formula: C₈H₈N₂O₂
• Molecular Weight: 164.16132
• Mol File: 36057-45-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 338.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -4.83±0.10(Predicted)
• CAS DataBase Reference: 3,5-DiMethoxypicolinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DiMethoxypicolinonitrile(36057-45-1)
• EPA Substance Registry System: 3,5-DiMethoxypicolinonitrile(36057-45-1)

Safety Data

• Hazardous Substances Data: 36057-45-1(Hazardous Substances Data)

Usage

General Description

3,5-Dimethoxypicolinonitrile is a chemical compound with the molecular formula C9H10N2O2. It is a nitrile derivative that is commonly used in the pharmaceutical and research industries as a building block for the synthesis of various organic compounds. This chemical is known for its potent biological activity and is used in the development of new drugs and pharmaceutical products. It is also used as a precursor in the synthesis of other chemical compounds, and its versatility and reactivity make it a valuable tool in organic chemistry research. Additionally, 3,5-Dimethoxypicolinonitrile is known for its unique properties and is widely studied for its potential applications in various fields.

Upstream product

• 298709-29-2 3,5-difluoropyridine-2-carbonitrile 
• 124-41-4 sodium methylate 

Relevant articles and documents

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation-incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.